InsiderDB
Sign inStart free trial

Rep. Robert P. Bresnahan, Jr. sold Viatris (VTRS)

Rep. Robert P. Bresnahan, Jr. (R-PA-8) · $1K–$15K · traded Apr 8, 2025

Transaction
Sold
Amount
$1K–$15K
Owner
Not stated
Traded
Apr 8, 2025
Disclosed
May 8, 2025
Days to disclose
30
Asset type
Stock
As filed
Viatris Inc. - Common Stock
Industry
Drug Manufacturers - Specialty & Generic · Healthcare
Official filing ↗All of Bresnahan's tradesAll Congress trades in VTRS

Other trades in this filing

All of Bresnahan's trades →

Recent Congress trades in VTRS

Company context for VTRS

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. VTRSLobbying report·Lobbying disclosures

    VTRS: third_quarter 2026 lobbying report

    S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act IP Issues related to generic medicines Patent Settlements Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act Policy related to corporate

    Public: Oct 20, 2026, 8:43 PM EDTOriginal source ↗
  2. VTRSLobbying report·Lobbying disclosures

    VTRS: third_quarter 2026 lobbying report

    Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071). Trade issues related to generic medicines.

    Public: Oct 19, 2026, 4:20 PM EDTOriginal source ↗
  3. VTRSLobbying report·Lobbying disclosures

    VTRS: third_quarter 2026 lobbying report

    S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.

    Public: Oct 7, 2026, 6:43 AM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.